Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 38%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne has demonstrated strong financial performance, reporting 9% organic growth in FQ2'25 driven by increased spending in the pharma and biotech sectors, resulting in a revenue beat of approximately 4%. The company's Protein Sciences and Diagnostics & Spatial Biology segments exhibited robust year-over-year growth rates of 8% and 12% respectively, underpinned by a favorable biopharmaceutical market and advancing cell therapy programs. Market trends indicate a positive trajectory with projected improvements in demand from biopharma customers, signaling potential for sustained revenue growth and enhanced profit margins in the future.

Bears say

Bio-Techne faces significant risks that may contribute to a negative outlook on its stock, including potentially overestimated revenue and earnings forecasts due to lower-than-anticipated demand for its products. The company is experiencing supply chain challenges, leading to inflated inventories and reduced equipment sales, with the slowdown in small biotech purchasing posing additional risks to future revenue. Furthermore, Bio-Techne's competitive position is threatened by larger, better-financed competitors and macroeconomic factors, including prolonged end-market weakness in life science tools and diagnostics, which could adversely impact future revenue and profitability.

Bio-Techne (TECH) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 38% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 21 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $160.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $160.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.